In a significant agreement with the Trump administration, AbbVie has committed to investing $100 billion in U.S. research and development, while also pledging to lower drug prices for millions of Americans. This deal includes tariff relief for the pharmaceutical company in exchange for the price cuts and an agreement to participate in the TrumpRx program, aimed at making medications more affordable. This strategic move is expected to alleviate costs on certain drugs and further enhance domestic investments in the pharmaceutical sector.